Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish

Epilepsy and Behavior

Volumn 45, Issue , 2015, Pages 53-63

  Leclercq, Karine ^a   Afrikanova, Tatiana ^b   Langlois, Melanie ^c   De Prins, An ^d   Buenafe, Olivia E ^b   Rospo, Chiara C ^a   Van Eeckhaut, Ann ^c   de Witte, Peter A M ^b   Crawford, Alexander D ^b,c   Smolders, Ilse ^d   Esguerra, Camila V ^b,e   Kaminski, Rafal M ^a  

^a UCB PHARMA   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^d FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Allylglycine; Antiepileptic drugs; Epilepsy; Seizures; Treatment resistance; Zebrafish

Indexed keywords

ALLYLGLYCINE; DIAZEPAM; ETIRACETAM; GLUTAMATE DECARBOXYLASE; NEUROTRANSMITTER; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BEHAVIOR CHANGE; BRAIN FUNCTION; CLONIC SEIZURE; CONTROLLED STUDY; CONVULSION; DRUG MEGADOSE; ELECTROGRAPHY; ENZYME INHIBITION; EPILEPTIC DISCHARGE; HIPPOCAMPUS; LARVA; LATENT PERIOD; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; ROTAROD TEST; SEIZURE; THERAPY RESISTANCE; TONIC SEIZURE; ZEBRA FISH;

EID: 84963936974     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.03.019     Document Type: Article

References (83)

1. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002, 50:105-123.
2. Remy S., Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006, 129:18-35.
3. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N Engl J Med 2011, 365:919-926.
4. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
5. Simonato M., Löscher W., Cole A.J., Dudek F.E., Engel J., Kaminski R.M., et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012, 53:1860-1867.
6. Galanopoulou A.S., Buckmaster P.S., Staley K.J., Moshé S.L., Perucca E., Engel J., et al. NIH public access. Epilepsia 2012, 53:571-582.
7. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
8. Kovács R., Heinemann U. Models in research of pharmacoresistant epilepsy: present and future in development of antiepileptic drugs. Curr Med Chem 2014, 21:689-703.
9. Volk H.A., Löscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005, 128:1358-1368.
10. Ebert U., Löscher W. Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: influence of genetic factors. Epilepsy Res 1999, 33:217-226.
11. Srivastava A.K., White H.S. Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats. Epilepsy Res 2013, 104:26-34.
12. Champagne D.L., Hoefnagels C.C.M., de Kloet R.E., Richardson M.K. Translating rodent behavioral repertoire to zebrafish (Danio rerio): relevance for stress research. Behav Brain Res 2010, 214:332-342.
13. Baraban S.C., Taylor M.R., Castro P.A., Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005, 131:759-768.
14. Baraban S.C., Dinday M.T., Castro P.A., Chege S., Guyenet S., Taylor M.R. A large-scale mutagenesis screen to identify seizure-resistant zebrafish. Epilepsia 2007, 48:1151-1157.
15. Afrikanova T., Serruys A-S K., Buenafe O.E.M., Clinckers R., Smolders I., de Witte P.A., et al. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLoS One 2013, 8:e54166.
16. Hortopan G.A., Dinday M.T., Baraban S.C. Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech 2010, 3:144-148.
17. Ramirez I.B.-R., Pietka G., Jones D.R., Divecha N., Alia A., Baraban S.C., et al. Impaired neural development in a zebrafish model for Lowe syndrome. Hum Mol Genet 2012, 21:1744-1759.
18. Chege S.W., Hortopan G.A., T Dinday M., Baraban S.C. Expression and function of KCNQ channels in larval zebrafish. Dev Neurobiol 2012, 72:186-198.
19. Mahmood F., Mozere M., Zdebik A.A., Stanescu H.C., Tobin J., Beales P.L., et al. Generation and validation of a zebrafish model of EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome. Dis Model Mech 2013, 6:652-660.
20. Baraban S., Dinday M., Hortopan G. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013, 4:2410.
21. Suls A., Jaehn J.A., Kecskés A., Weber Y., Weckhuysen S., Craiu D.C., et al. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 2013, 93:967-975.
22. Baxendale S., Holdsworth C.J., Santoscoy P.M., Harrison M.R.M., Fox J., Parkin C.A., et al. Identification of compounds with novel anti-convulsant properties in a zebrafish model of epileptic seizures. Dis Model Mech 2012, 5:773-784.
23. Mandhane S.N., Aavula K., Rajamannar T. Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. Seizure 2007, 16:636-644.
24. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999, 58:31-59.
25. Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl 2011, 124:5-15.
26. Moldrich R.X., Chapman A.G., De Sarro G., Meldrum B.S. Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur J Pharmacol 2003, 476:3-16.
27. Dingledine R. Glutamatergic mechanisms related to epilepsy: ionotropic receptors. Jasper's basic mechanisms of the epilepsies 2012, 122-131. National Center for Biotechnology Information (US), Bethesda (MD). 4th ed. J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta (Eds.).
28. Meldrum B. The role of glutamate in epilepsy and other CNS disorders. Neurology 1994, 44(Suppl. 8):14-23.
29. Meurs A., Clinckers R., Ebinger G., Michotte Y., Smolders I. Seizure activity and changes in hippocampal extracellular glutamate, GABA, dopamine and serotonin. Epilepsy Res 2008, 78:50-59.
30. Mehta A., Prabhakar M., Kumar P., Deshmukh R., Sharma P.L. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013, 698:6-18.
31. Gryder D.S., Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003, 23:7069-7074.
32. Rogawski M.A. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 2013, 127:9-18.
33. Scheyer R.D. Involvement of glutamate in human epileptic activities. Prog Brain Res 1998, 116:359-369.
34. Treiman D.M. GABAergic mechanisms in epilepsy. Epilepsia 2001, 42(Suppl. 3):8-12.
35. Mody I. Another "tonic" in the realm of epilepsy. Epilepsy Curr 2004, 4:248-249.
36. Lloyd K., Bossi L., Morselli P. Alterations of GABA-mediated synaptic transmission in human epilepsy. Adv Neurol 1986, 44:1033-1044.
37. Horton R.W. The role of 2-keto-4-pentenoic acid in seizures induced by allylglycine. Biochem Pharmacol 1978, 27:1471-1477.
38. Taberner P., Keen P. Brain and blood levels of allylglycine in mice following doses sufficient to inhibit glutamate decarboxylase. J Neurochem 1977, 29:595-597.
39. Chapman A.G. Regional changes in transmitter amino acids during focal and generalized seizures in rats. J Neural Transm 1985, 63:95-107.
40. Fisher S.K., Davies W.E. The effect of the convulsant allylglycine (2-amino-4-pentenoic acid) on the activity of glutamic acid decarboxylase and the concentration of GABA in different regions of guinea pig brain. Biochem Pharmacol 1976, 25:1881-1885.
41. Horton R.W., Meldrum B.S. Seizures induced by allylglycine, 3-mercaptopropionic acid and 4-deoxypyridoxine in mice and photosensitive baboons, and different modes of inhibition of cerebral glutamic acid decarboxylase. Br J Pharmacol 1973, 49:52-63.
42. Roper S. Inhibition of Mauthner cells by allylglycine. Nature 1970, 226:373-374.
43. Meldrum B.S., Chapman A.G., Horton R.W. Clobazam: anticonvulsant action in animal models of epilepsy [proceedings]. Br J Clin Pharmacol 1979, 7(Suppl. 1):59-60.
44. Nakamura J., Mine K., Yamada S. Effects of anticonvulsants on the electroconvulsive threshold lowered by DA, 5-HT or GABA depletion. Kurume Med J 1989, 37:253-259.
45. Ashton D., Wauquier A. Effects of some anti-epileptic, neuroleptic and gabaminergic drugs on convulsions induced by d,l-allylglycine. Pharmacol Biochem Behav 1979, 11:221-226.
46. Drago F., Valerio C., Clementi G., Scapagnini U. Effects of flunarizine on experimentally-induced convulsions in animals. Funct Neurol 1986, 1:529-532.
47. Sebe J., Baraban S. The promise of an interneuron-based cell therapy for epilepsy. Dev Neurobiol 2011, 71:107-117.
48. Marx M., Haas C.A., Häussler U. Differential vulnerability of interneurons in the epileptic hippocampus. Front Cell Neurosci 2013, 7:167.
49. Kitamura K., Yanazawa M., Sugiyama N., Miura H., Iizuka-Kogo A., Kusaka M., et al. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat Genet 2002, 32:359-369.
50. Kato M., Dobyns W.B. X-linked lissencephaly with abnormal genitalia as a tangential migration disorder causing intractable epilepsy: proposal for a new term, "interneuronopathy". J Child Neurol 2005, 20:392-397.
51. Friocourt G., Parnavelas J.G. Mutations in ARX result in several defects involving GABAergic neurons. Front Cell Neurosci 2010, 4:4.
52. Jones D.L., Howard M.A., Stanco A., Rubenstein J.L.R., Baraban S.C. Deletion of Dlx1 results in reduced glutamatergic input to hippocampal interneurons. J Neurophysiol 2011, 105:1984-1991.
53. Powell E.M., Campbell D.B., Stanwood G.D., Davis C., Noebels J.L., Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003, 23:622-631.
54. Eagleson K.L., Bonnin A., Levitt P. Region- and age-specific deficits in gamma-aminobutyric acidergic neuron development in the telencephalon of the uPAR(-/-) mouse. J Comp Neurol 2005, 489:449-466.
55. Valdés-Sánchez L., Escámez T., Echevarria D., Ballesta J.J., Tabarés-Seisdedos R., Reiner O., et al. Postnatal alterations of the inhibitory synaptic responses recorded from cortical pyramidal neurons in the Lis1/sLis1 mutant mouse. Mol Cell Neurosci 2007, 35:220-229.
56. Jones D.L., Baraban S.C. Characterization of inhibitory circuits in the malformed hippocampus of Lis1 mutant mice. J Neurophysiol 2007, 98:2737-2746.
57. Kawabata I., Kashiwagi Y., Obashi K., Ohkura M., Nakai J., Wynshaw-Boris A., et al. LIS1-dependent retrograde translocation of excitatory synapses in developing interneuron dendrites. Nat Commun 2012, 3:722.
58. Jones D.L., Baraban S.C. Inhibitory inputs to hippocampal interneurons are reorganized in Lis1 mutant mice. J Neurophysiol 2009, 102:648-658.
59. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47:217-227.
60. Racine R. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
61. Schauwecker P.E. Seizure-induced neuronal death is associated with induction of c-Jun N-terminal kinase and is dependent on genetic background. Brain Res 2000, 884:116-128.
62. Hortopan G.A., Dinday M.T., Baraban S.C. Spontaneous seizures and altered gene expression in GABA signaling pathways in a mind bomb mutant zebrafish. J Neurosci 2010, 30:13718-13728.
63. Van Hemelrijck A., Sarre S., Smolders I., Michotte Y. Determination of amino acids associated with cerebral ischaemia in rat brain microdialysates using narrowbore liquid chromatography and fluorescence detection. J Neurosci Methods 2005, 144:63-71.
64. Alberici M., Rodriguez de Lores Arna, De Robertis E. Glutamic acid decarboxylase inhibition and ultrastructural changes by the convulsant drug allylglycine. Biochem Pharmacol 1969, 18:137-143.
65. Barnwell L.F.S., Lugo J.N., Lee W.L., Willis S.E., Gertz S.J., Hrachovy R.A., et al. Kv4.2 knockout mice demonstrate increased susceptibility to convulsant stimulation. Epilepsia 2009, 50:1741-1751.
66. Pena F., Tapia R. Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience 2000, 101:547-561.
67. Tutka P., Mróz T., Klucha K., Piekarczyk M., Wielosz M. Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res 2005, 64:13-22.
68. Wilcox K.S., Dixon-Salazar T., Sills G.J., Ben-Menachem E., White H.S., Porter R.J., et al. Issues related to developments of new antiseizure treatments. Epilepsia 2013, 54:24-34.
69. Buenafe O.E., Orellana-Paucar A., Maes J., Huang H., Ying X., De Borggraeve W., et al. Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models. ACS Chem Neurosci 2013, 4:1479-1487.
70. Horton R., Meldrum B. A comparison of the effects of allylglycine and 2-keto-4-pentenoic acid on cerebral glutamic acid decarboxylase activity and convulsions in mice. Br J Pharmacol 1977, 3:477P.
71. 2-induced convulsions. Brain Res Bull 1980, 5:789-792.
72. Lima T.T., Begnini J., de Bastiani J., Fialho D.B., Jurach A., Ribeiro M.C., et al. Pharmacological evidence for GABAergic and glutamatergic involvement in the convulsant and behavioral effects of glutaric acid. Brain Res 1998, 802:55-60.
73. Esclapez M., Houser C. Up-regulation of GAD65 and GAD67 in remaining hippocampal GABA neurons in a model of temporal lobe epilepsy. J Comp Neurol 1999, 412:488-505.
74. Vianello M., Tavolato B., Giometto B. Glutamic acid decarboxylase autoantibodies and neurological disorders. Neurol Sci 2002, 23:145-151.
75. Gale K. Role of GABA in the genesis of chemoconvulsant seizures. Toxicol Lett 1992, 64-65. [Spec: 417-28].
76. Naylor D.E. Glutamate and GABA in the balance: convergent pathways sustain seizures during status epilepticus. Epilepsia 2010, 51(Suppl. 3):106-109.
77. Watanabe Y., Takechi K., Fujiwara A., Kamei C. Effects of antiepileptics on behavioral and electroencephalographic seizure induced by pentetrazol in mice. J Pharmacol Sci 2010, 112:282-289.
78. Holmes G., Zhao Q. Choosing the correct AED: from animal studies to the clinic. Pediatr Neurol 2008, 38:151-162.
79. Auta J., Impagnatiello F., Kadriu B., Guidotti A., Costa E. Imidazenil: a low efficacy agonist at alpha1 - but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem. Neuropharmacology 2008, 55:148-153.
80. Turski L., Stephens D., Jensen L., Petersen E., Meldrum B., Patel S., et al. Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther 1990, 253:344-352.
81. Johnson P., Lowry C., Truitt W., Shekhar A. Disruption of GABAergic tone in the dorsomedial hypothalamus attenuates responses in a subset of serotonergic neurons in the dorsal raphe nucleus following lactate-induced panic. J Psychopharmacol 2008, 22:642-652.
82. Johnson P.L., Samuels B.C., Fitz S.D., Federici L.M., Hammes N., Early M.C., et al. Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Physiol Behav 2012, 107:733-742.
83. Handley S.L., Singh L. Modulation of 5-hydroxytryptamine-induced head-twitch response by drugs acting at GABA and related receptors. Br J Pharmacol 1985, 86:297-303.